4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Candel Therapeutics, Inc. (CADL) operates in the Biotechnology industry and is headquartered in Needham, United States with about 55 employees. Its market capitalization is roughly $723 million. In the fiscal year ended 2025-12-31, CADL reported $0M in revenue and ($38M) in net income.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($48M) | ($33M) | ($38M) | ($35M) | — |
| Net Income | ($38M) | ($55M) | ($38M) | ($19M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($16M) | ($16M) | ($13M) | ($11M) | ($8M) |
| Net Income | ($9M) | ($30M) | ($11M) | ($5M) | $7M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $125M | $107M | $41M | $78M | — |
| Total Liabilities | $73M | $40M | $28M | $30M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CADL viewer.
About TickerBase · Data methodology & sources